Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo?s technology platform, which uses conformationally selective VHH antibodies ? ConfoBodies ? to stabilize GPCRs (G protein-coupled receptors) in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates. The agreement will leverage Confo?s expertise in addressing two GPCR targets for which functional antibodies are needed. Confo will be entitled to an upfront payment, research funding, and potential clinical, regulatory, and commercial payments. Confo?s ConfoBody-based technology platform aims to overcome the limitations of drug discovery on GPCRs, the large and most diverse group of membrane receptors targeted by approximately 30% of all commercialized drugs.